Literature DB >> 23640187

The intriguing future of pharmacoepidemiology.

Björn Wettermark1.   

Abstract

Over the years more and more data have become available in the constantly growing databases on prescription drugs. This has facilitated the development of pharmacoepidemiology, a dynamic research field that has undergone a more rapid development than many other research areas. There are several reasons why pharmacoepidemiology will remain recognized as one of the most dynamic and challenging research areas of clinical pharmacology. The data explosion in modern society will continue, and observational studies aimed at assessing the value of medicines will be increasingly requested by payers, professionals and patients. Future studies in pharmacoepidemiology must include specialist drugs used in the hospital setting and also be designed to address obstacles hindering the delivery of effective medicines to the patient. Pharmacoepidemiological methods may also be valuable tools to address new challenges, such as the environmental impact of medicines. A potential threat is that the increasing amounts of data available in registries may add fuel to the debate on confidentiality. The too strict application of privacy rules might hinder the further development of pharmacoepidemiology.

Entities:  

Mesh:

Year:  2013        PMID: 23640187     DOI: 10.1007/s00228-013-1496-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  41 in total

Review 1.  Introduction: a survey of international ethics practices in pharmacoepidemiology and drug safety.

Authors:  J F Merz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001-12       Impact factor: 2.890

2.  An application of propensity score matching using claims data.

Authors:  John D Seeger; Paige L Williams; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-07       Impact factor: 2.890

Review 3.  The Nordic countries as a cohort for pharmacoepidemiological research.

Authors:  Kari Furu; Björn Wettermark; Morten Andersen; Jaana E Martikainen; Anna Birna Almarsdottir; Henrik Toft Sørensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-04       Impact factor: 4.080

4.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

5.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 6.  Utilization of health care databases for pharmacoepidemiology.

Authors:  Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2011-08-02       Impact factor: 2.953

Review 7.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

8.  Drug utilization studies: a tool for determining the effectiveness of drug use.

Authors:  J R Laporte; M Porta; D Capella
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

9.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Authors:  J A Cramer; A Benedict; N Muszbek; A Keskinaslan; Z M Khan
Journal:  Int J Clin Pract       Date:  2007-11-05       Impact factor: 2.503

View more
  5 in total

1.  Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification.

Authors:  Enrica Menditto; Angela Bolufer De Gea; Caitriona Cahir; Alessandra Marengoni; Salvatore Riegler; Giuseppe Fico; Elisio Costa; Alessandro Monaco; Sergio Pecorelli; Luca Pani; Alexandra Prados-Torres
Journal:  Clinicoecon Outcomes Res       Date:  2016-06-13

2.  Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies.

Authors:  Stuart McTaggart; Clifford Nangle; Jacqueline Caldwell; Samantha Alvarez-Madrazo; Helen Colhoun; Marion Bennie
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

3.  Incidence in pharmacoepidemiology-Basic definitions and types of misclassification.

Authors:  Mikael Hoffmann; Henrik Støvring
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-04-13       Impact factor: 3.688

4.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10

5.  Data Sources for Drug Utilization Research in Brazil-DUR-BRA Study.

Authors:  Lisiane Freitas Leal; Claudia Garcia Serpa Osorio-de-Castro; Luiz Júpiter Carneiro de Souza; Felipe Ferre; Daniel Marques Mota; Marcia Ito; Monique Elseviers; Elisangela da Costa Lima; Ivan Ricardo Zimmernan; Izabela Fulone; Monica Da Luz Carvalho-Soares; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.